Matthew Reiss MSE PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer, and Jared Weiss MD, Section Chief of Thoracic and Head & Neck Oncology, Professor of Medicine, University of North Carolina at Chapel Hill It is [...]
Treatment strategies for non-small cell lung cancer (NSCLC) with EGFR mutations have evolved in recent years, including the development and approval of new therapies and combinations of treatments. The best treatment for each person with EGFR NSCLC depends on [...]
Question: I was diagnosed with early-stage lung cancer. Do I need biomarker testing? Can I benefit from a targeted therapy if a biomarker is discovered? (Answered by Dr. Collin Blakely from the University of California, San Francisco, during his [...]
Author: Andrew Ciupek, PhD, Associate Director, Clinical Research Targeted therapy research was front and center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Data was presented from several studies detailing new targeted therapies and better understanding [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung Cancer and Daniel A. Saez, MSc, Navigator, Treatment & Trials, GO2 for Lung CancerNew Hope for Patients with KRASUntil recently, the KRAS mutation was considered un-targetable in most types [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]